Cancer
Cancer Ongoing 2020

GU002

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel

Trial overview

Disease
Prostate cancer treatment & diagnosis
Topic
GU002
Description
Primary Objective To assess the benefit of docetaxel as measured by improvement in freedom from progression (phase II) and subsequently metastasis free survival (phase III) when given in combination with radiation and androgen deprivation in treatment of high risk prostate cancer post-radical prostatectomy.
Physicians

Dr. John Vito Antonucci

MD

Radiation Oncologist

Works at 4 centers.

Dr. Alvaro A. Martinez

MD, FACR, FABS, FASTRO

Radiation Oncologist

Works at 5 centers.

Dr. Michael I. Ghilezan

MD, PhD

Radiation Oncologist

Works at 4 centers.

Dr. Frank A. Vicini

MD, FACR, FASTRO

Radiation oncologist

Works at 3 centers.